News

Source — Source: ET ///Category — GS Paper 2 ///Published — 2026-03-03 ///Exam — Both Prelims and Mains ///Tags — Health, Blood Safety, Transfusion Medicine ///Source — Source: ET ///Category — GS Paper 2 ///Published — 2026-03-03 ///Exam — Both Prelims and Mains ///Tags — Health, Blood Safety, Transfusion Medicine ///

Source: ET · GS Paper 2

Nucleic Acid Amplification Testing

The Supreme Court of India has asked for detailed data on the cost, feasibility and infrastructure needed to introduce Nucleic Acid Amplification Testing (NAT) in government hospitals, following a PIL that seeks to declare a "Right to Safe Blood" under Article 21. The move could make NAT mandatory across blood banks, enhancing detection of transfusion‑transmitted infections such as HIV, HBV, HCV, malaria and syphilis.

2026-03-03

Published

Source: ET

Source

Quiz Questions

Article

Key Facts and Data Points

Supreme Court intervention: Seeking comprehensive details on cost, feasibility and infrastructure for NAT implementation in government hospitals.
PIL demand: Declaration of Right to Safe Blood as part of Article 21 (Right to Life).
Current legal framework: Drugs and Cosmetics Act, 1940 mandates only serological testing (e.g., ELISA) for blood screening; NAT is not yet compulsory.
NAT advantages:
Direct detection of viral RNA/DNA, drastically reducing the window period for HIV, HBV, HCV, malaria and syphilis.
Identifies false‑reactive donations, preventing unnecessary discarding of safe blood.
India’s thalassemia burden: Often called the "Thalassemia capital of the world"; patients need transfusions every 15‑20 days, making safe blood critical.
Reported incidents: Cases of HIV and Hepatitis transmission in Madhya Pradesh, Jharkhand and Uttar Pradesh due to unsafe transfusions.

Background and Context

Transfusion‑Transmitted Infections (TTIs) remain a major public‑health challenge.
Serological tests rely on the host’s antibody response, leading to a window period of weeks.
Nucleic Acid Amplification Testing (NAT) amplifies targeted viral nucleic acids, shortening the detection window to days.
Many developed nations have already made NAT mandatory for blood banks, setting a global best‑practice benchmark.

Significance for India / Governance / Policy

Infrastructure needs: Molecular labs, trained personnel, quality‑control mechanisms, and robust supply‑chain for reagents.
Financial implications: High initial capital outlay but long‑term savings by reducing TTI‑related treatment costs.
Policy alignment:
Supports the National Blood Policy (2002) and National Health Policy 2017 objectives of providing safe, quality‑assured blood.
Directly benefits vulnerable groups – thalassemia patients, hemophiliacs, obstetric emergencies, and trauma victims.
Judicial activism: The Supreme Court’s involvement may establish a precedent for recognizing health‑related rights as fundamental rights.

Related Constitutional / Legal Provisions

Article 21 – Right to life includes the right to health and safe blood.
Drugs and Cosmetics Act, 1940 – Currently mandates only serological screening.
National Blood Policy, 2002 – Recommends safe, quality‑assured blood and encourages adoption of advanced testing methods.
National Health Policy 2017 – Emphasises universal access to safe blood as part of comprehensive health care.